Journal article
P-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial
A Sonnenblick, R Salgado, S Brohée, T Zahavi, T Peretz, G Van Den Eynden, G Rouas, A Salmon, PA Francis, A Di Leo, JPA Crown, G Viale, L Daly, B Javdan, S Fujisawa, E De Azambuja, A Lieveke, MJ Piccart, JF Bromberg, C Sotiriou
International Journal of Oncology | SPANDIDOS PUBL LTD | Published : 2018
Abstract
In the present study, in order to investigate the role of signal transducer and activator of transcription 3 (STAT3) in estrogen receptor (ER)-positive breast cancer prognosis, we evaluated the phosphorylated STAT3 (p-STAT3) status and investigated its effect on the outcome in a pooled analysis and in a large prospective adjuvant trial. By using the TCGA repository, we developed gene signatures that reflected the level of p-STAT3. Using pooled analysis of the expression data from luminal breast cancer patients, we assessed the effects of the p-STAT3 expression signature on prognosis. We further validated the p-STAT3 prognostic effect using immunohistochemistry (IHC) and immunofluorescence st..
View full abstractGrants
Awarded by National Cancer Institute
Funding Acknowledgements
This study was funded by a Clinical Research Career Development Award from the Israel Cancer Research Fund grants (16-116-CRCDA) and from the Israeli Cancer Research Association (2017-0140).